![]() Or use the native HyperTRANSCRIBE Document (.htd) file as a source file in Researchware’s qualitative analysis software, HyperRESEARCH. When you’re finished transcribing, choose File ↠ Export to save your transcription as plain text, RTF (Rich Text Format), or SBV (YouTube subtitles and captions format). Enter your transcript in the right half of the transcription window as you play the media file.ĥ. Shift-Tab to back up to the previous segmentĤ.Tab to advance to the next segment and play it.Shift-space to play the current segment.Use the following shortcuts to play a segment at a time: When the file opens, the first five-second segment is selected and ready to play. At the top left corner of the transcription window, click Media File and choose the audio or video file you want to transcribe.ģ. To create a transcript with HyperTRANSCRIBE, follow these basic steps:ġ. When HyperTRANSCRIBE starts up, click New to create a new transcription window.(Or choose File ↠ New instead of clicking the button.)Ģ. Everything is done in a single transcription window, so there’s no need to switch between a play window and a text window. Instead, you use simple keyboard shortcuts that always leave your hands on the keyboard’s home row. Unlike software intended for professional transcribers, HyperTRANSCRIBE does not require the use of foot pedals or other equipment. Get the Latest Version of HyperTRANSCRIBE.Get the Latest Version of HyperRESEARCH.Institutional Site License Subscriptions.Government/Nonprofit Pricing & Ordering.Simply Powerful Tools for Qualitative Research Competing interests: The authors declare that they have no competing interests.Researchware, Inc. designed the experiments and wrote the article. provided experimental materials and cell-based models. reviewed the clinical and pathological data of TCGA. Using Apple Computers QuickTime® technology. HyperTRANSCRIBE lets you open and play most popular audio and video formats, and provides both graphical and keyboard control to play, pause, and loop playback so your hands never have to leave the keyboard. performed the experiments and analyzed the data. HyperTRANSCRIBE is ResearchWares software product for transcribing audio and video files. performed the experiments, analyzed the data, and wrote the article. were supported by the China Scholarship Council. Quantitative analysis refers to economic, business or financial analysis that aims to understand or predict behavior or events through the use of mathematical measurements and calculations. and L.Z.), the Kaleidoscope of Hope Ovarian Cancer Foundation (to L.Z.), and the Marsha Rivkin Center for Ovarian Cancer Research (to L.Z.). and L.Z.), the Foundation for Women’s Cancer (to X.H. and C.V.D.), the Ovarian Cancer Research Fund (to X.H. Funding: This work was supported, in whole or in part, by the Basser Center for BRCA (to L.Z.), the Harry Fields Professorship (to L.Z.), the NIH (R01CA142776, R01CA190415, P50CA083638, and P50CA174523 to L.Z., R01CA148759, R21CA198558, and U01CA200495 to Q.H., and R01NS094533 to Y.F.), the Breast Cancer Alliance (to L.Z. Qi (Harvard Medical School) for providing JQ1. Combination with BETi could greatly expand the utility of PARP inhibition to patients with HR-proficient cancer. Finally, we showed that the BRD4 gene was focally amplified across 20 types of common cancers. Moreover, BETi treatment sensitized tumors to PARP inhibition in preclinical animal models of HR-proficient breast and ovarian cancers. We also found that inhibition or depletion of BET proteins impairs transcription of BRCA1 and RAD51, two genes essential for HR. Functional assays demonstrated that repressed BET activity reduces HR and thus enhances PARPi-induced DNA damage in cancer cells. We used a drug synergy screen that combined a PARPi, olaparib, with 20 well-characterized epigenetic drugs and identified bromodomain and extraterminal domain inhibitors (BETis JQ1, I-BET762, and OTX015) as drugs that acted synergistically with olaparib in HR-proficient cancer cells. Strategies to enhance response to poly(adenosine diphosphate–ribose) polymerase inhibitor (PARPi) in primary and acquired homologous recombination (HR)–proficient tumors would be a major advance in cancer care.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |